Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
04:05pm, Wednesday, 13'th Nov 2024
BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body,
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expecte
Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)
01:20am, Thursday, 03'rd Oct 2024
On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totalin
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
09:28am, Saturday, 17'th Aug 2024
Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 16'th Aug 2024
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 16'th Jul 2024
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, toda
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation
Are Medical Stocks Lagging Annexon (ANNX) This Year?
10:45am, Friday, 28'th Jun 2024
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
10:55am, Thursday, 27'th Jun 2024
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 17'th Jun 2024
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 07'th Jun 2024
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Annexon Announces Pricing of $125 Million Underwritten Public Offering
11:04pm, Wednesday, 05'th Jun 2024
BRISBANE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
12:00pm, Wednesday, 05'th Jun 2024
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet
10:55am, Wednesday, 05'th Jun 2024
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
